Target intelligence / Profile preview

Urinary tract microbes (null)

Target
null
Molecular classification
Other (community of bacteria, fungi, viruses, archaea; not a discrete protein, enzyme, receptor, etc.)
01

Overview

Urinary tract microbes (the urinary microbiome) comprise bacteria, fungi, viruses, and occasionally archaea that inhabit the human urinary tract. These communities are crucial to urinary tract health, modulating immune function, protecting against pathogen colonization, and participating in metabolic activities[1][3][6][7]. Alterations in their composition (dysbiosis) are associated with urinary tract infections, recurrent infection, incontinence, urinary stone disease, and possibly systemic diseases[5][8]. The composition is highly variable between individuals and is influenced by host factors such as sex, urine pH, nutrient availability, and antibiotic use[1][3][6]. The community is not a therapeutic target in the conventional sense, but components and their interactions present indirect targets for non-antibiotic interventions such as probiotics, bacteriophage therapy, or FMT[2][4].

Other names
Urinary microbiomeurinary tract microbiotaurobiomeurinary resident microbes
02

Mechanism of action

Antibiotics: eradication or suppression of pathogenic microbes Probiotics: competitive inhibition, immune modulation, reduction of pathogen adhesion and biofilm formation Bacteriophages: targeted lysis of pathogenic bacteria Anti-adhesion molecules: block bacterial binding sites, prevent colonization

03

Biological functions

Urinary tract colonizationMaintenance of urinary tract healthModulation of immune responsesCompetition with pathogensBiofilm formationCarbohydrate and nutrient metabolism
04

Disease associations

Infection (most notably urinary tract infections, UTIs)Inflammation (bladder, kidney)Urinary stone disease (USD)Possible links to cardiovascular and metabolic diseasesOther (incontinence, chronic inflammatory conditions)
05

Safety considerations

Antibiotic resistance and persistence of uropathogenic bacteriaDisruption of beneficial microbial communities (dysbiosis)Inconsistent efficacy of probioticsPolymicrobial biofilms complicating eradicationPotential adverse effects from non-selective therapies (e.g., FMT)
06

Interacting drugs

Antibiotics (e.g., ciprofloxacin, nitrofurantoin, amoxicillin, trimethoprim)

4 more in the full profile.

07

Biomarkers

Species abundance/profiles (e.g., *Lactobacillus* spp., *Escherichia coli*, *Gardnerella vaginalis*)Reduced *Lactobacillus* abundance predictive of bladder disorders/incontinenceBiofilm formationMicrobial diversity indicesDetection of multidrug-resistant organisms (MDROs)

Beyond the preview

Go deeper on Urinary tract microbes (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urinary tract microbes (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call